Greeva Garg –
The research institute of the United States, the National Institute of Health (NIH) has assured Covaxin’s effectiveness against the pernicious Alpha and Delta variants of Covid-19.
Covaxin is India’s first indigenously formulated and developed Covid-19 vaccine, by India’s Bharat Biotech International Limited in Collaboration with the Indian Council of Medical Research (ICMR).
“Results from two studies of blood serum from people who had received Covaxin suggest that the vaccine generates antibodies that effectively neutralize the B.1.1.7 (Alpha) and B.1.617 (Delta) variants of SARS-CoV-2, first identified in the United Kingdom and India,” NIH said.
SARS-CoV-2 is a virus that causes Covid-19 disease.
Covaxin is formulated with the Alhydroxiquim-II, an adjuvant to boost immune responses against the Covid-19 virus and enhances the vaccine’s effectiveness.
NIH pointed out that, “Interim results from Covaxin’s Phase 3 trial have reportedly shown over 78% efficacy against symptomatic disease, 100% efficacy against severe infection and 70% efficacy against asymptomatic infection.”
Bharat Biotech said last month that, “It expects approval for its Covaxin from the World Health Organisation for emergency use listing during July-September.”
Covaxin has been dispensed to around 25 million people to date in India and elsewhere.
